.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,018,918

« Back to Dashboard

Details for Patent: 4,018,918

Title: Topical clindamycin preparations
Abstract:Disclosed is an anti-inflammatory compound, 6.alpha.,9.alpha.-di-fluoro-11.beta.,17.alpha.,21-trihydroxy-16.beta.-meth ylpregna-1,4-diene-3,20-dione 17,21-diacetate, and topical pharmaceutical formulations which include antimicrobial agents.
Inventor(s): Ayer; Donald E. (Kalamazoo, MI), Schlagel; Carl A. (Kalamazoo, MI), Flynn; Gordon L. (Ann Arbor, MI)
Assignee: The Upjohn Company (Kalamazoo, MI)
Filing Date:Mar 19, 1976
Application Number:05/668,389
Claims:1. A therapeutic composition for topical or local application for treatment of affected dermatosis comprising an anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate, an antibacterial therapeutic amount of clindamycin or pharmaceutically acceptable salt or ester thereof and an antifungal therapeutic amount of chloroxine in association with a pharmaceutical carrier.

2. A therapeutic composition according to claim 1, where the anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate is from about 0.01 percent to about 0.1 percent, where the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is from about 0.5 percent to about 2 percent and where the antifungal therapeutic amount of chloroxine is from about 1 percent to about 2 percent.

3. A therapeutic composition according to claim 1 where the anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate is 0.05 percent, where the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is 1 percent and where the antifungal therapeutic amount of chloroxine is not more than 1.5 percent.

4. A therapeutic composition according to claim 3 which is a cream.

5. The therapeutic composition according to claim 3 which is an ointment.

6. A therapeutic composition for topical or local application for treatment of infected dermatoses comprising an anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate and an antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof in association with a pharmaceutical carrier.

7. A therapeutic composition according to claim 6 where the anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.,21-trihydroxy-16.beta.-methylpregna-1,4-diene 3,20-dione 17,21-diacetate is from about 0.01 percent to about 0.1 percent and the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is from about 0.5 percent to about 2 percent.

8. A therapeutic composition according to claim 7 where the anti-inflammatory therapeutic amount of 6.alpha.,9.alpha.-difluoro-11.beta., 17.alpha.-21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate if 0.05 percent and the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is 1 percent.

9. A therapeutic composition according to claim 8, which is a cream.

10. A therapeutic composition according to claim 8, which is an ointment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc